Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer.
- WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer.
- "Lee has been part of the Q32 Bio team over the past five months as our interim Chief Financial Officer and an invaluable member of the team driving the execution and closing of our recent transactions.
- Prior to joining Q32 Bio, Mr. Kalowski served as President and Chief Financial Officer of Bicycle Therapeutics where he led strategic finance and operations and oversaw the company's transition to a public clinical-stage biotech company.
- Prior to Bicycle, Mr. Kalowski was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company's IPO in 2014.